PT-141
High EvidenceA melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women.
What It Is
PT-141 (bremelanotide, brand name Vyleesi) is a synthetic melanocortin peptide and the only FDA-approved treatment that targets the central nervous system to address sexual desire. Unlike PDE5 inhibitors such as sildenafil or tadalafil, which act peripherally on blood flow, PT-141 engages MC3R and MC4R receptors in the hypothalamus and brainstem — brain regions that regulate appetite, sexual behavior, and arousal. The FDA approved bremelanotide in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity. In pivotal Phase 3 trials (RECONNECT), 34% of bremelanotide-treated participants reported clinically meaningful improvement in desire compared to 9% on placebo. Nausea was the most common adverse event, affecting up to 40% of trial participants, though only 8.1% discontinued due to nausea. Bremelanotide causes a transient increase in blood pressure (approximately 6 mmHg systolic, 3 mmHg diastolic) and is contraindicated in patients with uncontrolled hypertension or cardiovascular disease. As of 2026, there is no FDA-approved indication for PT-141 in men, though preclinical and early clinical data demonstrated efficacy in male erectile dysfunction via the same central melanocortin pathway. The FDA's April 2026 Category 2 removal does not apply to PT-141, as it is already an approved drug. Ongoing research is exploring melanocortin receptor agonists for broader applications including eating disorders and social cognition.
Regulatory Status
Approved June 2019 as Vyleesi for acquired, generalized HSDD in premenopausal women. Subcutaneous injection, prescribed by licensed providers. Not approved for use in men.
Effective: June 2019
View FDA SourceWhy Researchers Study It
PT-141 is unique among sexual health compounds because it acts on brain circuits rather than vascular mechanisms. Its melanocortin receptor agonism provides a mechanistically distinct approach to desire disorders, making it a valuable research tool for understanding the neurobiology of sexual motivation and arousal.
Proposed Mechanisms
- Activates MC3R and MC4R melanocortin receptors in the hypothalamus and brainstem
- Modulates dopaminergic pathways involved in sexual motivation and reward
- Influences oxytocin release, which plays a role in arousal and bonding
- Acts centrally on desire circuits rather than peripheral vascular targets
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 3 RCT (RECONNECT) | Premenopausal women with HSDD | 34% of bremelanotide group reported meaningful improvement vs 9% placebo; statistically significant increase in desire and reduction in distress | Source |
| Phase 2 RCT | Men with erectile dysfunction | 51 subjects (34%) in bremelanotide group achieved erections sufficient for intercourse vs 9% placebo | Source |
| Phase 1 | Healthy males and females co-administered with ethanol | No clinically significant pharmacokinetic interaction with ethanol; safety profile maintained | Source |
Commonly Discussed Benefits
Safety & Cautions
- FDA-approved only for HSDD in premenopausal women
- Common side effects include nausea and flushing
- May increase blood pressure temporarily
- Must be prescribed and supervised by a physician
- Not for use in men (off-label use not recommended here)
Comparisons
See how PT-141 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Kingsberg SA. et al. — Bremelanotide for HSDD in premenopausal women: RECONNECT Phase 3 trials. Obstet Gynecol. 2019 PubMed
- [2] FDA Approval — Vyleesi (bremelanotide) prescribing information. 2019 PubMed
- [3] Diamond LE. et al. — PT-141 for erectile dysfunction: a melanocortin receptor agonist. Int J Impot Res. 2004 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Kisspeptin-10
Medium EvidenceA neuropeptide that stimulates GnRH release, studied for fertility and reproductive hormone regulation.
Oxytocin
High EvidenceA neuropeptide involved in social bonding, mood regulation, and reproductive functions.
MT-2 (Melanotan II)
Medium EvidenceA melanocortin receptor agonist studied for tanning, sexual function, and appetite suppression.